|
Market Cap (5-Jun) $132,782,144 (584th) |
Close (30-Jun) $0.040 |
Volume (30-Jun) 696,012 |
Shortsold (26-May) 9,980 (0.00%) (676th) |
|
52w High $0.072 |
52w Low $0.019 |
P/E 25.97 |
EPS -0.01 |
ACW released this announcement to the ASX on 13 May 2022, 9:12. The announcement is not marked as price sensitive, and is 2 page(s) in length and 191.3kb in size.
You can view all announcements from ACW and see how they appear on a price chart on the announcements page.
At the date of this announcement, ACW was 0.008% short sold according to ASIC data. It was ranked the 645th most shorted stock on the ASX. It remains ranked 676th as of the latest reported data (26 May 2026).
| Other Recent Announcements from ACW | |
|---|---|
| ACW CEO presentation on emerging oral Alzheimers therapies | 21 June 2023, 8:50 |
| ACW CEO & CMO present at BIO International Convention | 5 June 2023, 9:06 |
| ACW AD trial amendment and Clinical Science Forum slides | 24 May 2023, 8:20 |
| Appendix 3Y - Dr Steven Gourlay | 13 May 2022, 9:12 |
| Actinogen presentation to Bioshares Biotech Summit 2022 | 11 May 2022, 9:07 |
| Actinogen trial results & strategic update presentation | 4 May 2022, 9:16 |
| Actinogen prioritizes Alzheimers Disease & Depression | 4 May 2022, 9:14 |
You must be logged in to post a reply.
Actinogen Medical 